99 research outputs found
Properties of permutation-based gene tests and controlling type 1 error using a summary statistic based gene test
Background: The advent of genome-wide association studies has led to many novel disease-SNP associations, opening the door to focused study on their biological underpinnings. Because of the importance of analyzing these associations, numerous statistical methods have been devoted to them. However, fewer methods have attempted to associate entire genes or genomic regions with outcomes, which is potentially more useful knowledge from a biological perspective and those methods currently implemented are often permutation-based. Results: One property of some permutation-based tests is that their power varies as a function of whether significant markers are in regions of linkage disequilibrium (LD) or not, which we show from a theoretical perspective. We therefore develop two methods for quantifying the degree of association between a genomic region and outcome, both of whose power does not vary as a function of LD structure. One method uses dimension reduction to âfilterâ redundant information when significant LD exists in the region, while the other, called the summary-statistic test, controls for LD by scaling marker Z-statistics using knowledge of the correlation matrix of markers. An advantage of this latter test is that it does not require the original data, but only their Z-statistics from univariate regressions and an estimate of the correlation structure of markers, and we show how to modify the test to protect the type 1 error rate when the correlation structure of markers is misspecified. We apply these methods to sequence data of oral cleft and compare our results to previously proposed gene tests, in particular permutation-based ones. We evaluate the versatility of the modification of the summary-statistic test since the specification of correlation structure between markers can be inaccurate. Conclusion: We find a significant association in the sequence data between the 8q24 region and oral cleft using our dimension reduction approach and a borderline significant association using the summary-statistic based approach. We also implement the summary-statistic test using Z-statistics from an already-published GWAS of Chronic Obstructive Pulmonary Disorder (COPD) and correlation structure obtained from HapMap. We experiment with the modification of this test because the correlation structure is assumed imperfectly known
Recommended from our members
âLocation, Location, Locationâ: a spatial approach for rare variant analysis and an application to a study on non-syndromic cleft lip with or without cleft palate
Motivation: For the analysis of rare variants in sequence data, numerous approaches have been suggested. Fixed and flexible threshold approaches collapse the rare variant information of a genomic region into a test statistic with reduced dimensionality. Alternatively, the rare variant information can be combined in statistical frameworks that are based on suitable regression models, machine learning, etc. Although the existing approaches provide powerful tests that can incorporate information on allele frequencies and prior biological knowledge, differences in the spatial clustering of rare variants between cases and controls cannot be incorporated. Based on the assumption that deleterious variants and protective variants cluster or occur in different parts of the genomic region of interest, we propose a testing strategy for rare variants that builds on spatial cluster methodology and that guides the identification of the biological relevant segments of the region. Our approach does not require any assumption about the directions of the genetic effects. Results: In simulation studies, we assess the power of the clustering approach and compare it with existing methodology. Our simulation results suggest that the clustering approach for rare variants is well powered, even in situations that are ideal for standard methods. The efficiency of our spatial clustering approach is not affected by the presence of rare variants that have opposite effect size directions. An application to a sequencing study for non-syndromic cleft lip with or without cleft palate (NSCL/P) demonstrates its practical relevance. The proposed testing strategy is applied to a genomic region on chromosome 15q13.3 that was implicated in NSCL/P etiology in a previous genome-wide association study, and its results are compared with standard approaches. Availability: Source code and documentation for the implementation in R will be provided online. Currently, the R-implementation only supports genotype data. We currently are working on an extension for VCF files. Contact: [email protected]
Imputation of Orofacial Clefting Data Identifies Novel Risk Loci and Sheds Light on the Genetic Background of Cleft Lip ± Cleft Palate and Cleft Palate Only.
Abstract Nonsyndromic cleft lip with or without cleft palate (nsCL/P) is among the most common human birth defects with multifactorial etiology. Here, we present results from a genome-wide imputation study of nsCL/P in which, after adding replication cohort data, four novel risk loci for nsCL/P are identiïŹed (at chromosomal regions 2p21, 14q22, 15q24 and 19p13). On a systematic level, we show that the association signalswithin this high-density datasetare enriched in functionally-relevant genomic regions that are active in both human neural crest cells (hNCC) and mouse embryonic craniofacial tissue.
This enrichment is also detectable in hNCC regions primed for later activity. Using GCTA analyses, we suggest that 30% of the estimated variance in risk for nsCL/P in the European population can be attributed to common variants, with 25.5% contributed to by the 24 risk loci known to date. For each of these, we identify credible SNPs using a Bayesian reïŹnementapproach, with two loci harbouring only one probable causal variant. Finally, we demonstrate that there is no polygenic component of nsCL/P detectable that is shared with nonsyndromic cleft palate only (nsCPO). Our data suggest that, while common variants are strongly contributing to risk for nsCL/P, they do not seem to be involved in nsCPO which might be more often caused by rare deleterious variants. Our study generates novel insights into both nsCL/P and nsCPO etiology and provides a systematic framework for research into craniofacial development and malformation
Extending the allelic spectrum at noncoding risk loci of orofacial clefting
Genome-wide association studies (GWAS) have generated unprecedented insights into the genetic etiology of orofacial clefting (OFC). The moderate effect sizes of associated noncoding risk variants and limited access to disease-relevant tissue represent considerable challenges for biological interpretation of genetic findings. As rare variants with stronger effect sizes are likely to also contribute to OFC, an alternative approach to delineate pathogenic mechanisms is to identify private mutations and/or an increased burden of rare variants in associated regions. This report describes a framework for targeted resequencing at selected noncoding risk loci contributing to nonsyndromic cleft lip with/without cleft palate (nsCL/P), the most frequent OFC subtype. Based on GWAS data, we selected three risk loci and identified candidate regulatory regions (CRRs) through the integration of credible SNP information, epigenetic data from relevant cells/tissues, and conservation scores. The CRRs (total 57 kb) were resequenced in a multiethnic study population (1061 patients; 1591 controls), using single-molecule molecular inversion probe technology. Combining evidence from in silico variant annotation, pedigree- and burden analyses, we identified 16 likely deleterious rare variants that represent new candidates for functional studies in nsCL/P. Our framework is scalable and represents a promising approach to the investigation of additional congenital malformations with multifactorial etiology
Meta-analysis Reveals Genome-Wide Significance at 15q13 for Nonsyndromic Clefting of Both the Lip and the Palate, and Functional Analyses Implicate GREM1 As a Plausible Causative Gene
Nonsyndromic orofacial clefts are common birth defects with multifactorial etiology. The most common type is cleft lip, which occurs with or without cleft palate (nsCLP and nsCLO, respectively). Although genetic components play an important role in nsCLP, the genetic
factors that predispose to palate involvement are largely unknown. In this study, we carried out a meta-analysis on genetic and clinical data from three large cohorts and identified strong association between a region on chromosome 15q13 and nsCLP (P = 8.13Ă10â14 for
rs1258763; relative risk (RR): 1.46, 95% confidence interval (CI): 1.32â1.61)) but not nsCLO (P = 0.27; RR: 1.09 (0.94â1.27)). The 5 kb region of strongest association maps downstream of Gremlin-1 (GREM1), which encodes a secreted antagonist of the BMP4 pathway. We show during mouse embryogenesis, Grem1 is expressed in the developing lip and soft palate but not in the hard palate. This is consistent with genotype-phenotype correlations between rs1258763 and a specific nsCLP subphenotype, since a more than two-fold increase in risk was observed in patients displaying clefts of both the lip and soft palate but who had an intact hard palate (RR: 3.76, CI: 1.47â9.61, Pdiff<0.05). While we did not find lip or palate defects in Grem1-deficient mice, wild type embryonic palatal shelves developed divergent shapes when cultured in the presence of ectopic Grem1 protein (P = 0.0014). The present study identified a non-coding region at 15q13 as the second, genome-wide significant
locus specific for nsCLP, after 13q31. Moreover, our data suggest that the closely located GREM1 gene contributes to a rare clinical nsCLP entity. This entity specifically
involves abnormalities of the lip and soft palate, which develop at different time-points and in separate anatomical regions
Overlapping expression patterns and differential transcript levels of phosphate transporter genes in arbuscular mycorrhizal, Pi-fertilised and phytohormone-treated Medicago truncatula roots
A microarray carrying 5,648 probes of Medicago truncatula root-expressed genes was screened in order to identify those that are specifically regulated by the arbuscular mycorrhizal (AM) fungus Gigaspora rosea, by Pi fertilisation or by the phytohormones abscisic acid and jasmonic acid. Amongst the identified genes, 21% showed a common induction and 31% a common repression between roots fertilised with Pi or inoculated with the AM fungus G. rosea, while there was no obvious overlap in the expression patterns between mycorrhizal and phytohormone-treated roots. Expression patterns were further studied by comparing the results with published data obtained from roots colonised by the AM fungi Glomus mosseae and Glomus intraradices, but only very few genes were identified as being commonly regulated by all three AM fungi. Analysis of Pi concentrations in plants colonised by either of the three AM fungi revealed that this could be due to the higher Pi levels in plants inoculated by G. rosea compared with the other two fungi, explaining that numerous genes are commonly regulated by the interaction with G. rosea and by phosphate. Differential gene expression in roots inoculated with the three AM fungi was further studied by expression analyses of six genes from the phosphate transporter gene family in M. truncatula. While MtPT4 was induced by all three fungi, the other five genes showed different degrees of repression mirroring the functional differences in phosphate nutrition by G. rosea, G. mosseae and G. intraradices
Genome-wide association scan identifies new variants associated with a cognitive predictor of dyslexia
Developmental dyslexia (DD) is one of the most prevalent learning disorders, with high impact on school and psychosocial development and high comorbidity with conditions like attention-deficit hyperactivity disorder (ADHD), depression, and anxiety. DD is characterized by deficits in different cognitive skills, including word reading, spelling, rapid naming, and phonology. To investigate the genetic basis of DD, we conducted a genome-wide association study (GWAS) of these skills within one of the largest studies available, including nine cohorts of reading-impaired and typically developing children of European ancestry (N = 2562-3468). We observed a genome-wide significant effect (p <1 x 10(-8)) on rapid automatized naming of letters (RANlet) for variants on 18q12.2, within MIR924HG (micro-RNA 924 host gene; rs17663182 p = 4.73 x 10(-9)), and a suggestive association on 8q12.3 within NKAIN3 (encoding a cation transporter; rs16928927, p = 2.25 x 10(-8)). rs17663182 (18q12.2) also showed genome-wide significant multivariate associations with RAN measures (p = 1.15 x 10(-8)) and with all the cognitive traits tested (p = 3.07 x 10(-8)), suggesting (relational) pleiotropic effects of this variant. A polygenic risk score (PRS) analysis revealed significant genetic overlaps of some of the DD-related traits with educational attainment (EDUyears) and ADHD. Reading and spelling abilities were positively associated with EDUyears (p similar to [10(-5)-10(-7)]) and negatively associated with ADHD PRS (p similar to [10(-8)-10(-17)]). This corroborates a long-standing hypothesis on the partly shared genetic etiology of DD and ADHD, at the genome-wide level. Our findings suggest new candidate DD susceptibility genes and provide new insights into the genetics of dyslexia and its comorbities.Peer reviewe
Genome-wide association study reveals new insights into the heritability and genetic correlates of developmental dyslexia
Developmental dyslexia (DD) is a learning disorder affecting the ability to read, with a heritability of 40-60%. A notable part of this heritability remains unexplained, and large genetic studies are warranted to identify new susceptibility genes and clarify the genetic bases of dyslexia. We carried out a genome-wide association study (GWAS) on 2274 dyslexia cases and 6272 controls, testing associations at the single variant, gene, and pathway level, and estimating heritability using single-nucleotide polymorphism (SNP) data. We also calculated polygenic scores (PGSs) based on large-scale GWAS data for different neuropsychiatric disorders and cortical brain measures, educational attainment, and fluid intelligence, testing them for association with dyslexia status in our sample. We observed statistically significant (p <2.8 x 10(-6)) enrichment of associations at the gene level, forLOC388780(20p13; uncharacterized gene), and forVEPH1(3q25), a gene implicated in brain development. We estimated an SNP-based heritability of 20-25% for DD, and observed significant associations of dyslexia risk with PGSs for attention deficit hyperactivity disorder (atp(T) = 0.05 in the training GWAS: OR = 1.23[1.16; 1.30] per standard deviation increase;p = 8 x 10(-13)), bipolar disorder (1.53[1.44; 1.63];p = 1 x 10(-43)), schizophrenia (1.36[1.28; 1.45];p = 4 x 10(-22)), psychiatric cross-disorder susceptibility (1.23[1.16; 1.30];p = 3 x 10(-12)), cortical thickness of the transverse temporal gyrus (0.90[0.86; 0.96];p = 5 x 10(-4)), educational attainment (0.86[0.82; 0.91];p = 2 x 10(-7)), and intelligence (0.72[0.68; 0.76];p = 9 x 10(-29)). This study suggests an important contribution of common genetic variants to dyslexia risk, and novel genomic overlaps with psychiatric conditions like bipolar disorder, schizophrenia, and cross-disorder susceptibility. Moreover, it revealed the presence of shared genetic foundations with a neural correlate previously implicated in dyslexia by neuroimaging evidence.Peer reviewe
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
AG has received support by NordForsk Nordic Trial Alliance (NTA) grant, by Academy of
Finland Fellow grant N. 323116 and the Academy of Finland for PREDICT consortium N.
340541.
The Richards research group is supported by the Canadian Institutes of Health Research
(CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the
Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK,
Genome Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in
Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported
by a research fellowship of the Japan Society for the Promotion of Science for Young
Scientists. GBL is supported by a CIHR scholarship and a joint FRQS and Québec Ministry of
Health and Social Services scholarship. JBR is supported by an FRQS Clinical Research
Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is
funded by the Welcome Trust, the Medical Research Council, the European Union, the
National Institute for Health Research-funded BioResource and the Clinical Research Facility
and Biomedical Research Centre based at Guyâs and St. Thomasâ NHS Foundation Trust in
partnership with Kingâs College London. The Biobanque QuĂ©bec COVID19 is funded by FRQS,
Genome Québec and the Public Health Agency of Canada, the McGill Interdisciplinary
Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé. These funding
agencies had no role in the design, implementation or interpretation of this study.
The COVID19-Host(a)ge study received infrastructure support from the DFG Cluster of
Excellence 2167 âPrecision Medicine in Chronic Inflammation (PMI)â (DFG Grant: âEXC2167â).
The COVID19-Host(a)ge study was supported by the German Federal Ministry of Education
and Research (BMBF) within the framework of the Computational Life Sciences funding
concept (CompLS grant 031L0165). Genotyping in COVID19-Host(a)ge was supported by a
philantropic donation from Stein Erik Hagen.
The COVID GWAs, Premed COVID-19 study (COVID19-Host(a)ge_3) was supported by
"Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia"and also by
the Instituto de Salud Carlos III (CIBERehd and CIBERER). Funding comes from
COVID-19-GWAS, COVID-PREMED initiatives. Both of them are supported by "Consejeria de
Salud y Familias" of the Andalusian Government. DMM is currently funded by the the
Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018).
The Columbia University Biobank was supported by Columbia University and the National
Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official
views of the NIH or Columbia University.
The SPGRX study was supported by the ConsejerĂa de EconomĂa, Conocimiento, Empresas y
Universidad #CV20-10150.
The GEN-COVID study was funded by: the MIUR grant âDipartimenti di Eccellenza 2018-2020â
to the Department of Medical Biotechnologies University of Siena, Italy; the âIntesa San Paolo
2020 charity fundâ dedicated to the project NB/2020/0119; and philanthropic donations to the
Department of Medical Biotechnologies, University of Siena for the COVID-19 host genetics
research project (D.L n.18 of March 17, 2020). Part of this research project is also funded by
Tuscany Region âBando Ricerca COVID-19 Toscanaâ grant to the Azienda Ospedaliero
Universitaria Senese (CUP I49C20000280002). Authors are grateful to: the CINECA
consortium for providing computational resources; the Network for Italian Genomes (NIG)
(http://www.nig.cineca.it) for its support; the COVID-19 Host Genetics Initiative
(https://www.covid19hg.org/); the Genetic Biobank of Siena, member of BBMRI-IT, Telethon
Network of Genetic Biobanks (project no. GTB18001), EuroBioBank, and RD-Connect, for
managing specimens.
Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was
supported by Ricerca Corrente (Italian Ministry of Health), intramural funding (Fondazione
Humanitas per la Ricerca). The generous contribution of Banca Intesa San Paolo and of the
Dolce&Gabbana Fashion Firm is gratefully acknowledged.
Data acquisition and sample processing was supported by COVID-19 Biobank, Fondazione
IRCCS CĂ Granda Milano; LV group was supported by MyFirst Grant AIRC n.16888, Ricerca
Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS
Caâ Granda Ospedale Maggiore Policlinico, the European Union (EU) Programme Horizon
2020 (under grant agreement No. 777377) for the project LITMUS- âLiver Investigation:
Testing Marker Utility in Steatohepatitisâ, Programme âPhotonicsâ under grant agreement
â101016726â for the project âREVEAL: Neuronal microscopy for cell behavioural examination
and manipulationâ, Fondazione Patrimonio Caâ Granda âLiver Bibleâ PR-0361. DP was
supported by Ricerca corrente Fondazione IRCCS Caâ Granda Ospedale Maggiore Policlinico,
CV PREVITAL âStrategie di prevenzione primaria nella popolazione Italianaâ Ministero della
Salute, and Associazione Italiana per la Prevenzione dellâEpatite Virale (COPEV).
Genetic modifiers for COVID-19 related illness (BeLCovid_1) was supported by the "Fonds
Erasme". The Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2)
study was supported by grants from Fondation LĂ©on Fredericq and from Fonds de la
Recherche Scientifique (FNRS).
The INMUNGEN-CoV2 study was funded by the Consejo Superior de Investigaciones
CientĂficas.
KUL is supported by the German Research Foundation (LU 1944/3-1) SweCovid is funded by the SciLifeLab/KAW national COVID-19 research program project
grant to Michael Hultström (KAW 2020.0182) and the Swedish Research Council to Robert
Frithiof (2014-02569 and 2014-07606). HZ is supported by Jeansson Stiftelser, Magnus
Bergvalls Stiftelse.
The COMRI cohort is funded by Technical University of Munich, Munich, Germany.
Genotyping for the COMRI cohort was performed and funded by the Genotyping Laboratory of
Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki,
Helsinki, Finland.
These funding agencies had no role in the design, implementation or interpretation of this
study.Background: There is considerable variability in COVID-19 outcomes amongst younger
adultsâand some of this variation may be due to genetic predisposition. We characterized the
clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent
effect, using individual-level data in a large international multi-centre consortium.
Method: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by
the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive
patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this
genetic marker with mortality, COVID-19-related complications and laboratory values. We next
examined if the magnitude of these associations varied by age and were independent from
known clinical COVID-19 risk factors.
Findings: We found that rs10490770 risk allele carriers experienced an increased risk of
all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2â1·6) and COVID-19
related mortality (HR 1·5, 95%CI 1·3â1·8). Risk allele carriers had increased odds of several
COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6),
venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI
1·2-2·0). Risk allele carriers †60 years had higher odds of death or severe respiratory failure
(OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction
p-value=0·04). Amongst individuals †60 years who died or experienced severe respiratory
COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers,
compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes.
Prediction of death or severe respiratory failure among those †60 years improved when
including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770
risk allele was similar to, or better than, most established clinical risk factors.
Interpretation: The major common COVID-19 risk locus on chromosome 3 is associated with
increased risks of morbidity and mortalityâand these are more pronounced amongst individuals
†60 years. The effect on COVID-19 severity was similar to, or larger than most established risk
factors, suggesting potential implications for clinical risk management.Academy of
Finland Fellow grant N. 323116Academy of Finland for PREDICT consortium N.
340541.Canadian Institutes of Health Research
(CIHR) (365825 and 409511)Lady Davis Institute of the Jewish General HospitalCanadian Foundation for Innovation (CFI)NIH FoundationCancer Research UKGenome QuébecPublic Health Agency of CanadaMcGill Interdisciplinary Initiative in
Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS)Japan Society for the Promotion of Science for Young
ScientistsCIHR scholarship and a joint FRQS and Québec Ministry of
Health and Social Services scholarshipFRQS Clinical Research
ScholarshipCalcul QuébecCompute CanadaWelcome TrustMedical Research CouncEuropean UnionNational Institute for Health Research-funded BioResourceClinical Research Facility
and Biomedical Research Centre based at Guyâs and St. Thomasâ NHS Foundation TrustKingâs College LondonGenome QuĂ©becPublic Health Agency of CanadaMcGill Interdisciplinary
Initiative in Infection and ImmunityFonds de Recherche QuĂ©bec SantĂ©(DFG Grant: âEXC2167â)(CompLS grant 031L0165)Stein Erik Hagen"Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia"Instituto de Salud Carlos III (CIBERehd and CIBERER)COVID-19-GWASCOVID-PREMED initiatives"Consejeria de
Salud y Familias" of the Andalusian GovernmentAndalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018)Columbia UniversityNational
Center for Advancing Translational SciencesNIH Grant Number UL1TR001873ConsejerĂa de EconomĂa, Conocimiento, Empresas y
Universidad #CV20-10150MIUR grant âDipartimenti di Eccellenza 2018-2020ââIntesa San Paolo
2020 charity fundâ dedicated to the project NB/2020/0119Tuscany Region âBando Ricerca COVID-19 ToscanaâCINECA
consortiumNetwork for Italian Genomes (NIG)COVID-19 Host Genetics InitiativeGenetic Biobank of SienaEuroBioBankRD-ConnectRicerca Corrente (Italian Ministry of Health)Fondazione
Humanitas per la RicercaBanca Intesa San PaoloDolce&Gabbana Fashion FirmCOVID-19 BiobankFondazione
IRCCS CĂ Granda MilanoMyFirst Grant AIRC n.16888Ricerca
Finalizzata Ministero della Salute RF-2016-02364358Ricerca corrente Fondazione IRCCS
Caâ Granda Ospedale Maggiore PoliclinicoEuropean Union (EU) Programme Horizon
2020 (under grant agreement No. 777377)âPhotonicsâ â101016726âFondazione Patrimonio Caâ Granda âLiver Bibleâ PR-0361CV PREVITAL âStrategie di prevenzione primaria nella popolazione Italianaâ Ministero della
Salute, and Associazione Italiana per la Prevenzione dellâEpatite Virale (COPEV)"Fonds
Erasme"Fondation LĂ©on FredericqFonds de la
Recherche Scientifique (FNRS)Consejo Superior de Investigaciones
CientĂficasGerman Research Foundation (LU 1944/3-1)SciLifeLab/KAW national COVID-19 research program project (KAW 2020.0182)Swedish Research Council (2014-02569 and 2014-07606)Jeansson Stiftelser, Magnus
Bergvalls StiftelseTechnical University of Munich, Munich, GermanyGenotyping Laboratory of
Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki,
Helsinki, Finlan
- âŠ